.Nature Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a typical consequence of 11 months, people with metastatic intestinal growths that obtained biomarker-matched treatments based upon distributing lump DNA profiling presented a greater clinical benefit than those receiving unequaled therapy.